Neurozentrum Bielefeld
- Address
- Hauptstr. 102, 33647 Bielefeld, Germany
Neurozentrum Bielefeld - Psychiatric Research Center
Neurozentrum Bielefeld is a specialized neuropsychiatric research facility focused on advancing treatment options for mental health disorders. The center demonstrates particular expertise in conducting sophisticated clinical trials that integrate modern genetic biomarker approaches with traditional pharmacological interventions.
- Major Depressive Disorder treatment development and novel antidepressant therapies
- Precision psychiatry utilizing polygenic scoring for patient stratification
- Phase II randomized controlled trials with placebo-controlled designs
The center's research methodology emphasizes personalized medicine approaches in psychiatry, particularly through the application of V1b receptor genetics and biomarker-guided treatment selection. Their work in outpatient depression management reflects a commitment to translating genetic insights into clinical practice, potentially enabling more targeted and effective therapeutic interventions for patients with mood disorders.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1Celgene Corp.1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AbbVie Deutschland GmbH & Co. KG2trials
lock +1 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Neurozentrum Bielefeld
lock Showing 1 of 6 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized, Double-blind, Parallel-group, Active Controlled Trial with Open-label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE) | AbbVie Deutschland GmbH & Co. KG | Phase III | Not Recruiting | Jan 2024 | May 2026 |
IMP list
lock Showing 1 of 6 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Atogepant | 2 | Unknown | 2024-01-17 | 2025-03-05 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.